Paolo Nuciforo
Paolo Nuciforo
Molecular Pathologist, VHIO
Verified email at
Cited by
Cited by
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
R Di Micco, M Fumagalli, A Cicalese, S Piccinin, P Gasparini, C Luise, ...
Nature 444 (7119), 638-642, 2006
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
S Bullman, CS Pedamallu, E Sicinska, TE Clancy, X Zhang, D Cai, ...
Science 358 (6369), 1443-1448, 2017
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
S Carreira, J Goodall, L Denat, M Rodriguez, P Nuciforo, KS Hoek, ...
Genes & development 20 (24), 3426-3439, 2006
Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311, 2017
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib …
R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ...
JAMA oncology 1 (4), 448-455, 2015
Assessing tumor infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235, 2017
NUMB controls p53 tumour suppressor activity
IN Colaluca, D Tosoni, P Nuciforo, F Senic-Matuglia, V Galimberti, G Viale, ...
Nature 451 (7174), 76-80, 2008
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ...
Annals of oncology 25 (9), 1729-1735, 2014
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R Dienstmann, J Rodon, A Prat, J Perez-Garcia, B Adamo, E Felip, ...
Annals of oncology 25 (3), 552-563, 2014
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response
C Gorrini, M Squatrito, C Luise, N Syed, D Perna, L Wark, F Martinato, ...
Nature 448 (7157), 1063-1067, 2007
Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
A Prat, A Navarro, L Paré, N Reguart, P Galván, T Pascual, A Martínez, ...
Cancer research 77 (13), 3540-3550, 2017
Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma
PG Nuciforo, C Pellegrini, R Fasani, M Maggioni, G Coggi, A Parafioriti, ...
Human Pathology 34 (7), 639-645, 2003
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ...
Annals of Oncology 29 (5), 1203-1210, 2018
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer …
A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ...
The lancet oncology 18 (4), 545-554, 2017
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer
IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, ...
Journal of Clinical Oncology 33 (12), 1334, 2015
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ...
Annals of oncology 26 (7), 1280-1291, 2015
Frequent alterations in the expression of serine/threonine kinases in human cancers
M Capra, PG Nuciforo, S Confalonieri, M Quarto, M Bianchi, M Nebuloni, ...
Cancer research 66 (16), 8147-8154, 2006
Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor–negative melanoma …
J Goodall, S Carreira, L Denat, D Kobi, I Davidson, P Nuciforo, RA Sturm, ...
Cancer research 68 (19), 7788-7794, 2008
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer
JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ...
Cancer research 77 (9), 2213-2221, 2017
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ...
EMBO molecular medicine 10 (12), e9172, 2018
The system can't perform the operation now. Try again later.
Articles 1–20